ABC-transporter expression does not correlate with response to irinotecan in patients with metastatic colorectal cancer

Journal of Cancer

Volumn 6, Issue 11, 2015, Pages 1079-1086

  Trumpi, K ^a   Emmink, B L ^a   Prins, A M ^a   van Oijen, M G H ^a,b   van Diest, P J ^a   Punt, C J A ^b   Koopman, M ^a   Kranenburg, O ^a   Borel Rinkes, I H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ABC transporters; ABCB1; ABCG2; CAIRO; Chemotherapy; Irinotecan; Metastatic colorectal cancer

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAPECITABINE; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY;

EID: 84947733560     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.12606     Document Type: Article

References (28)

1. Koopman M, Punt CJ. Chemotherapy, which drugs and when. European journal of cancer. 2009; 45 Suppl 1: 50-6.
2. Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Current medicinal chemistry. 2012; 19: 3874-85.
3. Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. British journal of cancer. 2012; 106: 18-24.
4. Emmink BL, Van Houdt WJ, Vries RG, Hoogwater FJ, Govaert KM, Verheem A, et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology. 2011; 141: 269-78.
5. te Velde EA, Vogten JM, Gebbink MF, van Gorp JM, Voest EE, Borel Rinkes IH. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. The British journal of surgery. 2002; 89: 1302-9.
6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews Cancer. 2002; 2: 48-58.
7. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. International journal of cancer Journal international du cancer. 2004; 109: 848-54.
8. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer metastasis reviews. 2007; 26: 39-57.
9. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, Tsui WY, et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 15418-23.
10. Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Molecular pharmaceutics. 2006; 3: 87-93.
11. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer research. 2001; 61: 3458-64.
12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences of the United States of America. 1987; 84: 7735-8.
13. Middleton G, Brown S, Lowe C, Maughan T, Gwyther S, Oliver A, et al. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European journal of cancer. 2013; 49: 3507-16.
14. Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic oncology. 2011; 122: 116-20.
15. Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, van der Valk P, van Kalken CK, et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 1995; 6: 679-85.
16. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2012; 15: 62-9.
17. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007; 370: 135-42.
18. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. British journal of cancer. 2009; 100: 266-73.
19. Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L, et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC genomics. 2013; 14: 589.
20. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26: 2690-8.
21. Berlth F, Monig SP, Schlosser HA, Maus M, Baltin CT, Urbanski A, et al. Validation of 2-mm tissue microarray technology in gastric cancer. Agreement of 2-mm TMAs and full sections for Glut-1 and Hif-1 alpha. Anticancer research. 2014; 34: 3313-20.
22. Goethals L, Perneel C, Debucquoy A, De Schutter H, Borghys D, Ectors N, et al. A new approach to the validation of tissue microarrays. The Journal of pathology. 2006; 208: 607-14.
23. Batistatou A, Televantou D, Bobos M, Eleftheraki AG, Kouvaras E, Chrisafi S, et al. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. Anticancer research. 2013; 33: 2139-45.
24. Veenendaal LM, Kranenburg O, Smakman N, Klomp A, Borel Rinkes IH, van Diest PJ. Differential Notch and TGFbeta signaling in primary colorectal tumors and their corresponding metastases. Cellular oncology: the official journal of the International Society for Cellular Oncology. 2008; 30: 1-11.
25. Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochemical pharmacology. 2009; 78: 1366-73.
26. Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer letters. 2014; 347: 159-66.
27. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al. Cancer cell adaptation to chemotherapy. BMC cancer. 2005; 5: 78.
28. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine. 2012; 366: 883-92.